RxDoctor Payments Data

Mohammad Kooshkabadi, MD

Clinical Cardiac Electrophysiology · Atlanta, GANPI 1740464189

Payments from drug & device makers

$13,951in general payments, 2019–2025

Across 263 payments — averaging $53.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$9K
  • Cvrx, Inc.$1K
  • Abbott$418
  • Boston Scientific$355
  • Pfizer$345
  • Boehringer Ingelheim$343
  • plus $2K from 22 others

What the payments were for

  • Travel & lodging$3,21723%
  • Food & beverage$10,73477%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,951 in reported general payments places this provider in the 30th percentile of 93 clinical cardiac electrophysiology providers in Georgia.

See all clinical cardiac electrophysiology providers in Georgia

Medicare billing

Part B allowed, 2024
$219,496
Medicare patients
871
Services billed
2,728

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban586$618,712
XareltoRivaroxaban85$90,007
EntrestoSacubitril/Valsartan66$69,798
JardianceEmpagliflozin49$64,616
FarxigaDapagliflozin Propanediol19$24,749
BrilintaTicagrelor14$11,052
Dofetilide36$8,577
Amiodarone Hcl152$4,258
Metoprolol Succinate264$3,288
SotalolSotalol Hcl178$2,014
Flecainide Acetate77$1,581
Nadolol31$1,358
Carvedilol191$1,232
Rosuvastatin Calcium103$1,215
Valsartan58$1,209

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$345$618,712586 claims
Johnson & JohnsonXarelto$179$90,00785 claims
NovartisEntresto$107$69,79866 claims
Boehringer IngelheimJardiance$343$64,61649 claims
AstraZenecaFarxiga, Brilinta$100$35,80233 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 93 clinical cardiac electrophysiology providers in Georgia.

Other clinical cardiac electrophysiology in Atlanta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →